AGA Guideline Recommendations for Autonomic Dysfunction Screening and Management in hEDS

Screening Recommendations

• The 2025 American Gastroenterological Association (AGA) Clinical Practice Update states that universal testing for postural tachycardia syndrome (POTS) or other autonomic dysfunction in all patients with hypermobile Ehlers‑Danlos syndrome (hEDS) is not supported by current evidence (expert consensus). 1
• Autonomic screening should be targeted to individuals with hEDS who present with clinical manifestations of orthostatic intolerance—such as palpitations, dizziness, presyncope, syncope, or light‑headedness (moderate‑quality evidence). 1
• Referral for formal autonomic testing is recommended for hEDS patients with refractory gastrointestinal symptoms who also report orthostatic intolerance after exclusion of medication side‑effects and after appropriate lifestyle modifications have been attempted (expert consensus). 3

Clinical Red‑Flag Indicators Warranting Autonomic Evaluation

• Symptoms that improve when the patient sits or lies down (expert consensus). 1
• Exacerbation of symptoms with food ingestion, physical exertion, or heat exposure (expert consensus). 1
• Palpitations or tachycardia that occur upon standing (expert consensus). 1
• Gastrointestinal dysmotility symptoms (e.g., bloating, early satiety, constipation) that suggest autonomic involvement (moderate‑quality evidence). 4

First‑Line Non‑Pharmacologic Management for Confirmed POTS/Autonomic Dysfunction

• Fluid and Salt Optimization – Encourage substantially increased daily fluid intake and liberalized dietary sodium (expert consensus). 3
• Structured Exercise Training – Implement supervised cardiovascular fitness programs aimed at maintaining conditioning despite symptoms (expert consensus). 3
• Compression Garments – Recommend use of compression stockings or abdominal binders to mitigate venous pooling (expert consensus). 3

Pharmacologic Treatment Indications

• Pharmacologic therapy should be reserved for patients with moderate‑to‑severe functional impairment who have failed to achieve adequate symptom control with the above conservative measures, and should involve coordinated care among cardiology, neurology, and gastroenterology (expert consensus). 3

Evidence Gaps and Clinical Caveats

• The guideline highlights limited experimental evidence linking hEDS pathophysiology to dysautonomia, indicating a need for further mechanistic research (low‑quality evidence). 2
• Potential confounding by medications (e.g., stimulants, centrally acting agents) may influence autonomic test results (expert consensus). 1
• Many studies have applied inconsistent 2017 hEDS diagnostic criteria, which may affect prevalence estimates and generalizability (expert consensus). 1
• Overall, the AGA emphasizes that clinical screening should focus on symptomatic orthostatic intolerance rather than pursuing universal autonomic testing in all hEDS patients (expert consensus). [1][2]